Apimeds Pharmaceuticals US, Inc.
APUS NYSE· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.90
KIRA · Stoqly’s AI analyst, in plain words
- Apimeds Pharmaceuticals US, Inc. lost $6.0M in fiscal 2025.
- Free cash flow was −$9.0M in fiscal 2025, — of revenue.
Market cap
$5.0M
P/E
—
Revenue
—
Net income
−$6.0M
Free cash flow
−$9.0M
Operating margin
—
Apimeds Pharmaceuticals US, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$6.0M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Apimeds Pharmaceuticals US, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · May 4, 2026
- Legal name
- Apimeds Pharmaceuticals US, Inc.
- CIK
- 0001894525
Apimeds Pharmaceuticals US, Inc. · APUS
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$0.8M | −$1.4M | −$6.0M |
| Diluted EPS | −$0.17 | −$0.18 | −$0.55 |
| Cash | |||
| Cash from operations | −$0.6M | −$0.7M | −$8.9M |
| Capital expenditure | — | — | $0.1M |
| Free cash flow | — | — | −$9.0M |
| Share count change | — | — | 37.7% |
| Debt and strength | |||
| Cash and short-term investments | $0.4M | $0.0M | $3.6M |
| Deposits | — | — | $8.0M |
| Shareholders' equity | $0.0M | −$1.4M | $153M |
| Current ratio | 3.4x | 0.0x | 1.3x |
| Interest coverage | −19.6x | −10.8x | −42.1x |
| Returns and quality | |||
| Return on equity | −2,437.9% | — | −7.9% |
| Return on tangible equity | −2,437.9% | — | −3.9% |
| Altman Z'' | −30.4 | −2,254.5 | 14.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Apimeds Pharmaceuticals US, Inc. · APUS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.90 a share, the company is worth $5.0M.
Source: SEC EDGAR XBRL filings (CIK 0001894525). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.